These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30916320)

  • 1. PRMT1 loss sensitizes cells to PRMT5 inhibition.
    Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
    Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
    Chen H; Lorton B; Gupta V; Shechter D
    Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective PRMT5 Inhibitors Suppress Human CD8
    Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
    Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.
    Zheng S; Moehlenbrink J; Lu YC; Zalmas LP; Sagum CA; Carr S; McGouran JF; Alexander L; Fedorov O; Munro S; Kessler B; Bedford MT; Yu Q; La Thangue NB
    Mol Cell; 2013 Oct; 52(1):37-51. PubMed ID: 24076217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
    Fong JY; Pignata L; Goy PA; Kawabata KC; Lee SC; Koh CM; Musiani D; Massignani E; Kotini AG; Penson A; Wun CM; Shen Y; Schwarz M; Low DH; Rialdi A; Ki M; Wollmann H; Mzoughi S; Gay F; Thompson C; Hart T; Barbash O; Luciani GM; Szewczyk MM; Wouters BJ; Delwel R; Papapetrou EP; Barsyte-Lovejoy D; Arrowsmith CH; Minden MD; Jin J; Melnick A; Bonaldi T; Abdel-Wahab O; Guccione E
    Cancer Cell; 2019 Aug; 36(2):194-209.e9. PubMed ID: 31408619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
    Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
    J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR
    Li M; An W; Xu L; Lin Y; Su L; Liu X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):64. PubMed ID: 30736843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells.
    Chuang CY; Chang CP; Lee YJ; Lin WL; Chang WW; Wu JS; Cheng YW; Lee H; Li C
    Oncol Rep; 2017 Aug; 38(2):1115-1123. PubMed ID: 28656289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase.
    Burgos ES; Wilczek C; Onikubo T; Bonanno JB; Jansong J; Reimer U; Shechter D
    J Biol Chem; 2015 Apr; 290(15):9674-89. PubMed ID: 25713080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEP50/PRMT5 Reduces Gene Expression by Histone Arginine Methylation and this Is Reversed by PKCδ/p38δ Signaling.
    Saha K; Adhikary G; Eckert RL
    J Invest Dermatol; 2016 Jan; 136(1):214-224. PubMed ID: 26763441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
    J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
    Sheng X; Wang Z
    BMC Cancer; 2016 Aug; 16():567. PubMed ID: 27480244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
    Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
    Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylosome Protein 50 and PKCδ/p38δ Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression.
    Saha K; Eckert RL
    J Biol Chem; 2015 May; 290(21):13521-30. PubMed ID: 25851901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells.
    Chatterjee B; Ghosh K; Suresh L; Kanade SR
    Mol Cell Biochem; 2019 May; 455(1-2):73-90. PubMed ID: 30392062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
    Dong Y; Song C; Wang Y; Lei Z; Xu F; Guan H; Chen A; Li F
    Cell Signal; 2017 Jun; 34():55-65. PubMed ID: 28302565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.